Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

PURPOSE: Pertuzumab is a humanized monoclonal antibody inhibiting human epidermal growth factor receptor 2 (HER2) dimerization. The aim of this phase II trial was to assess the antitumor activity and safety profile of pertuzumab monotherapy in patients with HER2-negative metastatic breast cancer. Th...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Gianni, Luca, Lladó, Anna, Bianchi, Giulia, Cortes, Javier, Kellokumpu-Lehtinen, Pirkko-Liisa, Cameron, David A., Miles, David, Salvagni, Stefania, Wardley, Andrew, Goeminne, Jean-Charles, Hersberger, Veronica, Baselga, José
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2010
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979215/
https://ncbi.nlm.nih.gov/pubmed/20124183
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.24.1661
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires